Evaluating genetic changes in lung cancer patients after oxitinib treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the characteristics of genetic mutations in patients with EGFRm non-small cell lung cancer (NSCLC) before and after three weeks of treatment with oxitinib. It is a multicenter, non-interventional, real-world study that focuses on understanding the efficacy of oxitinib and the mechanisms of treatment resistance. Blood samples will be collected to assess molecular markers at baseline and after treatment, providing insights into the genetic variations associated with the therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female,age ≥18 years.
2. Newly diagnosed,histologically confirmed,and classified as stage IIIB,IIIC,IV or recurrent NSCLC which are not amenable to curative surgery or radiotherapy .
3. No prior systemic antitumor therapy, including EGFR -TKIs or immunotherapy .
4. Presence of an EGFR mutation confirmed by a local laboratory in blood or tissue samples .
5. Adequate blood samples available for molecular testing .
6. Provision of written informed consent .

Exclusion Criteria:

1. Inability to provide plasma samples at baseline .
2. Baseline blood EGFR mutation status not confirmed by the central laboratory .
3. Refusal to receive subsequent treatment with osimertinib .
4. Any condition that ,in the investigator's judgment ,could interfere with study procedures or confound outcome assessment .

Where it's running

• Cancer Hospital Chinese
  Beijing, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Izalontamab Brengitecan with Osimertinib in EGFR-mutant NSCLC: first-line versus standard options

  This study tests whether adding iza-bren to osimertinib can help people with newly diagnosed EGFR-mutant non-small cell lung cancer, compared with osimertinib alone or osimertinib plus platinum-based chemotherapy.

  Recruiting at 10 sites Phase 3 Bristol-Myers Squibb · Beverly Hills, California and 204 other locations · NCT07680790

• BL-B01D1 with Osimertinib before/around surgery for EGFR-mutant resectable NSCLC

  A Phase II/III trial tests if adding BL-B01D1 to osimertinib around surgery helps people with resectable EGFR-mutant non-small cell lung cancer.

  Recruiting at 2 sites Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT07642024

• Barriers and facilitators to sticking with osimertinib after early-stage NSCLC

  This study asks how adults with early-stage NSCLC in China continue or stop adjuvant osimertinib, by talking with patients and doctors to understand what helps or hinders persistence.

  Recruiting AstraZeneca · Beijing · NCT07542210

• Ivonescimab with datopotamab deruxtecan or osimertinib for EGFR‑mutant non‑small cell lung cancer

  This trial will test whether combining ivonescimab with datopotamab deruxtecan or with osimertinib is safe and helps people with metastatic EGFR‑mutant non‑small cell lung cancer who have already received third‑generation EGFR inhibitors and chemotherapy.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07535437

• Boosting Osimertinib brain penetration with febuxostat in EGFR-mutated NSCLC

  This study tests whether adding febuxostat to osimertinib can increase osimertinib levels in the brain for patients with EGFR-mutated NSCLC who do not have CNS metastases.

  Recruiting Phase 2 Maastricht University Medical Center · Amsterdam and 1 other locations · NCT07485452

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.